O
OABI
vs
S&P 500
S&P 500
Over the past 12 months, OABI has underperformed S&P 500, delivering a return of -50% compared to the S&P 500's +16% growth.
Stocks Performance
OABI vs S&P 500
Performance Gap
OABI vs S&P 500
Performance By Year
OABI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
OmniAb Inc
Glance View
OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 93 full-time employees. The company went IPO on 2020-10-09. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. Its OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach and OmniTaur features structural attributes of cow antibodies for complex targets. The firm's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic targets.
